

John A Lawson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7092014/publications.pdf>

Version: 2024-02-01

60
papers

2,954
citations

257357

24
h-index

175177

52
g-index

62
all docs

62
docs citations

62
times ranked

3287
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet</i> , 2016, 388, 2153-2163.	6.3	554
2	<i>GRIN2B</i> encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. <i>Journal of Medical Genetics</i> , 2017, 54, 460-470.	1.5	190
3	Validation of a New Quality of Life Measure for Children with Epilepsy. <i>Epilepsia</i> , 2000, 41, 765-774.	2.6	185
4	TuberOus SCLerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 2.	1.2	166
5	The Health-Related Quality of Life of Children with Refractory Epilepsy: A Comparison of Those With and Without Intellectual Disability. <i>Epilepsia</i> , 2001, 42, 621-628.	2.6	145
6	Mammalian Target of Rapamycin Inhibitors for Intractable Epilepsy and Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. <i>Journal of Pediatrics</i> , 2014, 164, 1195-1200.	0.9	139
7	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. <i>JAMA Neurology</i> , 2021, 78, 285.	4.5	139
8	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 157.	1.2	106
9	Cerebral and Cerebellar Volume Reduction in Children with Intractable Epilepsy. <i>Epilepsia</i> , 2000, 41, 1456-1462.	2.6	96
10	Everolimus for treatment-refractory seizures in TSC. <i>Neurology: Clinical Practice</i> , 2018, 8, 412-420.	0.8	85
11	Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 186-199.	0.6	83
12	Management Strategies for CLN2 Disease. <i>Pediatric Neurology</i> , 2017, 69, 102-112.	1.0	80
13	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 495-504.	2.7	77
14	Ten-Year Single-Center Experience of the Ketogenic Diet: Factors Influencing Efficacy, Tolerability, and Compliance. <i>Journal of Pediatrics</i> , 2015, 166, 1030-1036.e1.	0.9	66
15	Eye movement disorders are an early manifestation of <i>CACNA1A</i> mutations in children. <i>Developmental Medicine and Child Neurology</i> , 2016, 58, 639-644.	1.1	58
16	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SCLerosis registry to increase disease Awareness. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 502-508.	0.4	55
17	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 1066-1073.	0.7	54
18	Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. <i>Neurology</i> , 2021, 96, e1770-e1782.	1.5	53

#	ARTICLE	IF	CITATIONS
19	Everolimus dosing recommendations for <scp>tuberous sclerosis complexâ€“</scp>associated refractory seizures. <i>Epilepsia</i> , 2018, 59, 1188-1197.	2.6	41
20	ILAE-Defined Epilepsy Syndromes in Children: Correlation with Quantitative MRI. <i>Epilepsia</i> , 1998, 39, 1345-1349.	2.6	33
21	Outcomes of deviation from treatment guidelines in status epilepticus: A systematic review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 58, 147-153.	0.9	32
22	Cannabidiol for treating drugâ€“resistant epilepsy in children: the New South Wales experience. <i>Medical Journal of Australia</i> , 2018, 209, 217-221.	0.8	28
23	Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome. <i>Pediatric Neurology</i> , 2017, 76, 20-26.	1.0	27
24	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. <i>Frontiers in Neurology</i> , 2020, 11, 972.	1.1	27
25	Clinicopathological associations in temporal lobe epilepsy patients utilising the current ILAE focal cortical dysplasia classification. <i>Epilepsy Research</i> , 2014, 108, 1345-1351.	0.8	25
26	Theory of Mind and social competence in children and adolescents with genetic generalised epilepsy (GGE): Relationships to epilepsy severity and anti-epileptic drugs. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 60, 96-104.	0.9	23
27	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex â€“ Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. <i>Frontiers in Pharmacology</i> , 2018, 9, 964.	1.6	22
28	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2019, 10, 705.	1.1	22
29	Quantitative MRI in Outpatient Childhood Epilepsy. <i>Epilepsia</i> , 1997, 38, 1289-1293.	2.6	20
30	Frequency and predictors of psychological distress after a diagnosis of epilepsy: A community-based study. <i>Epilepsy and Behavior</i> , 2017, 75, 190-195.	0.9	20
31	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. <i>Frontiers in Neurology</i> , 2020, 11, 904.	1.1	20
32	Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth. <i>Pediatric Dermatology</i> , 2016, 33, 536-542.	0.5	18
33	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. <i>Frontiers in Neurology</i> , 2019, 10, 821.	1.1	18
34	Clustered mutations in the GRIK2 kainate receptor subunit gene underlie diverse neurodevelopmental disorders. <i>American Journal of Human Genetics</i> , 2021, 108, 1692-1709.	2.6	18
35	The Severity of Gliosis in Hippocampal Sclerosis Correlates with Pre-Operative Seizure Burden and Outcome After Temporal Lobectomy. <i>Molecular Neurobiology</i> , 2016, 53, 5446-5456.	1.9	17
36	The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review. <i>Reviews in the Neurosciences</i> , 2018, 29, 295-301.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 24.	1.5	16
38	Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. <i>Haematologica</i> , 2022, 107, 635-643.	1.7	16
39	Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. <i>Epilepsia</i> , 2021, 62, 3029-3041.	2.6	16
40	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the Tuberous Sclerosis registry to increase disease awareness (TOSCA). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 301.	1.2	15
41	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. <i>Frontiers in Neurology</i> , 2021, 12, 697467.	1.1	13
42	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. <i>Frontiers in Neurology</i> , 2019, 10, 1144.	1.1	11
43	Efficacy and safety of cannabidiol treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. <i>Epilepsia</i> , 2022, 63, 1736-1747.	2.6	11
44	Facial emotion perception and social competence in children (8 to 16 years old) with genetic generalized epilepsy and temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , 2019, 100, 106301.	0.9	10
45	Tuberous Sclerosis registry to increase disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2021, 12, 630378.	1.1	10
46	Exploring carer perceptions of training in out-of-hospital use of buccal midazolam for emergency management of seizures (2008-2012). <i>Journal of Paediatrics and Child Health</i> , 2015, 51, 704-707.	0.4	8
47	Therapeutic use of medicinal cannabis in difficult to manage epilepsy. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2488-2490.	1.1	8
48	Accelerated long-term forgetting in children with genetic generalized epilepsy: The temporal trajectory and contribution of executive skills. <i>Epilepsy and Behavior</i> , 2020, 113, 107471.	0.9	8
49	Expert advice for prescribing cannabis medicines for patients with epilepsy" drawn from the Australian clinical experience. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3101-3113.	1.1	8
50	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. <i>Frontiers in Neurology</i> , 2020, 11, 603.	1.1	7
51	Managing tuberous sclerosis in the Asia-Pacific region: Refining practice and the role of targeted therapy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1180-1187.	0.8	6
52	Cannabis for paediatric epilepsy: challenges and conundrums. <i>Medical Journal of Australia</i> , 2018, 208, 132-136.	0.8	6
53	Anti-N-methyl-D-aspartate encephalitis " a case study of symptomatic progression. <i>Australasian Psychiatry</i> , 2015, 23, 422-425.	0.4	5
54	Management of status epilepticus in children prior to medical retrieval: Deviations from the guidelines. <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 1458-1462.	0.4	5

#	ARTICLE	IF	CITATIONS
55	Congenital subependymal giant cell astrocytoma in children with tuberous sclerosis complex: growth patterns and neurological outcome. <i>Pediatric Research</i> , 2021, 89, 1447-1451.	1.1	5
56	Accelerated long-term forgetting in children with temporal lobe epilepsy: A timescale investigation of material specificity and executive skills. <i>Epilepsy and Behavior</i> , 2022, 129, 108623.	0.9	4
57	The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases. <i>Frontiers in Neurology</i> , 2019, 10, 1182.	1.1	3
58	The need for improved management of status epilepticus in children in Australia: Time from seizure onset to treatment is consistently delayed. <i>Journal of Paediatrics and Child Health</i> , 2021, , .	0.4	3
59	Successful epilepsy surgery for tuberous sclerosis complex evaluated by stereoelectroencephalography. <i>Epileptic Disorders</i> , 2020, 22, 633-641.	0.7	1
60	Response to “About Focal Cortical Dysplasia (FCD) type IIIa” • <i>Epilepsy Research</i> , 2014, 108, 1958-1959.	0.8	0